Pharmaceutical

Erasca trims workforce and pipeline to focus on KRAS and molecular glues

Erasca has made operational cuts while licensing a molecular glue therapy and a KRAS inhibitor for $22.5m upfront.

May 19, 2024 - 04:00
Erasca trims workforce and pipeline to focus on KRAS and molecular glues
Erasca has made operational cuts while licensing a molecular glue therapy and a KRAS inhibitor for $22.5m upfront.
Read the original article

Tags:

Previous Article

Sanders issues warning to Novo Nordisk amid GLP-1 drug price investigation

Next Article

Galapagos enters deal to boost decentralised CAR-T therapy production

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT+: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker

Opinion: STAT+: Dana-Farber CEO Laurie Glimcher has alw...

Dec 11, 2023

Opinion: How Medicare leaves Puerto Ricans behind

Opinion: How Medicare leaves Puerto Ricans behind

Feb 21, 2024

STAT+: To prevent emergency C-sections, researchers turn to AI to predict the course of childbirth

STAT+: To prevent emergency C-sections, researchers tur...

Mar 19, 2023